EVICEL Receives FDA Approval

An adjunct to hemostasis in patients undergoing liver surgery when control of bleeding by conventional surgical techniques, including suture, ligature, and cautery is ineffective or impractical. Not indicated for the treatment of massive and brisk arterial bleeding.
The U.S. Food and Drug Administration (FDA) today approved Evicel Fibrin Sealant, a liquid product that when applied topically helps control oozing from small blood vessels during surgical procedures.
EVICEL Fibrin Sealant (Human) is prepared from human plasma. As with all plasma-derived products, the potential to transmit infectious agents cannot be completely eliminated, including viruses and the Creutzfeldt-Jakob disease agent.